Brought to you by 
Series A brings $1.3mm to Euclises Pharmaceuticals; $700k added
07 Apr 2015
Executive Summary
Euclises Pharmaceuticals Inc. (oncology) raised $1.3mm through its Series A round led by Cultivation Capital. Life sciences accelerator BioGenerator also participated, along with Missouri Technology Corp., ABC Laboratories, the St. Louis Port Authority’s Helix Fund, and seed investors the St. Louis Arch Angels. BioGenerator and St. Louis Arch Angels join the board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings $1.3mm to Euclises Pharmaceuticals; $700k added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice